References
All links accessed on February 2025
1. NICE guideline NG220. ‘Multiple sclerosis in adults: management’. Published: 22 June 2022 https://www.nice.org.uk/guidance/ng220
2. MS Society.’ What is MS?’. https://www.mssociety.org.uk/about-ms/what-is-ms
3. Multiple Sclerosis Trust. ‘What is MS?’. Last updated April 1st 2022. https://mstrust.org.uk/information-support/about-ms/what-is-ms
4. MS International Federation. ‘Types of MS’. Last updated March 12th 2022. https://www.msif.org/about-ms/types-of-ms/
5. Multiple Sclerosis Trust. ‘Types of MS’. Last updated October 1st 2020 https://mstrust.org.uk/information-support/about-ms/types-ms
6. Overcoming MS. ‘Types of MS’. https://overcomingms.org/about-multiple-sclerosis/types-of-ms
7. Multiple Sclerosis Trust. ‘Disease modifying drugs (DMDs)’. Last updated March 1st 2022. https://mstrust.org.uk/information-support/ms-drugs-treatments/disease-modifying-drugs-dmds
8. NICE technology appraisal guidance TA706. ‘Ozanimod for treating relapsing–remitting multiple sclerosis’. Published June 9th 2021. https://www.nice.org.uk/guidance/ta706
9. Multiple Sclerosis Trust. ‘Life expectancy’. Last updated March 12 2024. https://mstrust.org.uk/a-z/life-expectancy
10. Multiple Sclerosis Trust. ‘Frequently asked questions (FAQs)’. https://mstrust.org.uk/information-support/ms-drugs-treatments/ms-decisions/frequently-asked-questions-faqs
11. Electronic Medicines Compendium (emc). Summaries of Product Characteristics (various). https://www.medicines.org.uk/emc#gref
12.NICE. Multiple sclerosis. https://www.nice.org.uk/guidance/conditions-and-diseases/neurological-conditions/multiple-sclerosis
13. Health Improvement Scotland / Scottish Medicines Consortium. Medicines advice. https://scottishmedicines.org.uk/medicines-advice/
14. Cleveland Clinic Neurological Institute. ‘Disease-Modifying Therapy Discontinuation in Multiple Sclerosis’. https://my.clevelandclinic.org/departments/neurological/depts/multiple-sclerosis/ms-approaches/disease-modifying-therapy-discontinuation-in-multiple-sclerosis
15. MS Society. ‘Flu jabs, vaccines and MS’. Last reviewed September 13th 2023. https://www.mssociety.org.uk/living-with-ms/health-and-social-care/health-care/flu-jabs
16. JR Corboy et al. ‘Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial’. The Lancet Neurology. July 2023. 22;7:568-577. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00154-0/abstract